Alnylam Pharmaceuticals, Inc. (LON:0HD2)
London
· Delayed Price · Currency is GBP · Price in USD | Market Cap | 30.69B |
| Revenue (ttm) | 1.82B |
| Net Income (ttm) | -208.75M |
| Shares Out | n/a |
| EPS (ttm) | -1.62 |
| PE Ratio | n/a |
| Forward PE | 228.83 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7 |
| Average Volume | 177 |
| Open | 318.00 |
| Previous Close | 315.88 |
| Day's Range | 316.82 - 319.92 |
| 52-Week Range | 209.75 - 325.00 |
| Beta | n/a |
| RSI | 68.14 |
| Earnings Date | Aug 7, 2025 |
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc. discovers, develops, and commercializes therapeutics based on ribonucleic acid interference. It offers ONPATTRO and AMVUTTRA for hereditary transthyretin-mediated amyloidosis; GIVLAARI for acute hepatic porphyria; OXLUMO for primary hyperoxaluria type 1; and Leqvio for hypercholesterolemia. It also develops vutrisiran, which is in phase III clinical trial for transthyretin amyloidosis (ATTR) with cardiomyopathy; Nucresiran that is in phase I clinical trial for ATTR amyloidosis; Fitusiran, which is in phase III clin... [Read more]
Financial Performance
In 2024, Alnylam Pharmaceuticals's revenue was $2.25 billion, an increase of 22.97% compared to the previous year's $1.83 billion. Losses were -$278.16 million, -36.82% less than in 2023.
Financial numbers in USD Financial StatementsNews
Alnylam Pharmaceuticals Names Garg R&D Chief
Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed E...
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted...
Moderna Beats Alnylam Appeal In COVID Vaccine Patent Case
The U.S. Court of Appeals for the Federal Circuit (CAFC) on Wednesday affirmed a district court’s finding of noninfringement in favor of Moderna, Inc. (NASDAQ: MRNA) in its ongoing patent battle with...
Why Alnylam Could Outperform In The Transthyretin Amyloidosis With Cardiomyopathy Field
Vutrisiran, recently FDA-approved for ATTR-CM, offers strong efficacy and a favorable safety profile compared to competitors. See why I rate ALNY stock a Hold.
Alnylam to Webcast Presentation at Goldman Sachs 46th Annual Global Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the Goldman S...
Here's How Much $1000 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 20 years by 12.14% on an annualized basis producing an average annual return of 20.3%. Currently, Alnylam Pharmaceutic...
Alnylam Issues 2024 Corporate Responsibility Report
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today the publication of its 2024 Corporate Responsibility Report. Gui...
Alnylam posts new Phase 3 data for heart disease therapy Amvuttra
AMVUTTRA® (vutrisiran) Significantly Reduces Mortality and a Range of Important Cardiovascular Events in Patients with ATTR Amyloidosis with Cardiomyopathy: Additional Data from HELIOS-B
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today presented the most contemporary analysis of the HELIOS-B Phase 3 study of ...
Alnylam to Share Progress Across its Transthyretin Amyloidosis Franchise Including Additional Analyses of the HELIOS-B Phase 3 Study Results at Heart Failure 2025 Congress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced that the Company will present the latest data from its flagship ...
$100 Invested In Alnylam Pharmaceuticals 15 Years Ago Would Be Worth This Much Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 15 years by 8.93% on an annualized basis producing an average annual return of 20.2%. Currently, Alnylam Pharmaceutica...
Alnylam to Webcast Presentation at BofA Securities 2025 Health Care Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Secu...
Alnylam Delivers Q1 Surprise, Analysts Highlight Amvuttra Momentum, Limited Tariff Risk
Alnylam Pharmaceuticals Inc (NASDAQ: ALNY) on Thursday reported a first-quarter 2025 adjusted EPS loss of 1 cent, beating the consensus loss of $(1.03) . The company reported quarterly sales of $594....
Apple To Rally More Than 17%? Here Are 10 Top Analyst Forecasts For Friday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page . Telsey Ad...
Biogen Beats Q1 Earnings Expectations As Two Newcomer Drug Sales Spike, Avoids Tariff Impact
Biogen Inc. (NASDAQ: BIIB) reported on Thursday that the first quarter of 2025 adjusted earnings per share was $3.02. That’s down from $3.67 a year ago, beating the analyst consensus of $2.52 . The c...
Alnylam Pharmaceuticals, Inc. 2025 Q1 - Results - Earnings Call Presentation
The following slide deck was published by Alnylam Pharmaceuticals, Inc.
Alnylam reiterates 2025 guidance with projected 36% growth in TTR franchise revenues
Alnylam Pharmaceuticals, Inc. (ALNY) Q1 2025 Earnings Call Transcript
$100 Invested In Alnylam Pharmaceuticals 20 Years Ago Would Be Worth This Much Today
Alnylam Pharmaceuticals (NASDAQ: ALNY) has outperformed the market over the past 20 years by 11.06% on an annualized basis producing an average annual return of 19.26%. Currently, Alnylam Pharmaceuti...
Alnylam Pharmaceuticals Non-GAAP EPS of -$0.01 beats by $0.36, revenue of $594.19M beats by $9.42M
Alnylam Pharmaceuticals Reports First Quarter 2025 Financial Results and Highlights Recent Period Progress
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended Ma...
Alnylam Pharmaceuticals Q1 2025 Earnings Preview
Alnylam, Halozyme among latest firms to win EU backing for drugs
EMA panel supports Alnylam & Halozyme drugs' marketing approval for rare diseases. Read more here.
Alnylam Receives Positive CHMP Opinion for Vutrisiran for the Treatment of ATTR Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the Committee for Medicinal Products for...